Flagship explainer

How IMMUNITYBIO, INC. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$113M · 100%Cost of revenue$753000 · 1%Gross profit$113M · 99%Operating income−$256M · −226%Income before tax−$352M · −310%Income tax−$135000 · −0%Net income−$351M · −310%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$113M100%
Cost of revenue$7530001%
$113M99%
−$256M−226%
Income before tax−$352M−310%
Income tax−$135000−0%
−$351M−310%
Source: · event Dec 31, 2025 · retrieved Jul 26, 2026 · annual-row source set
Embed this chart

View the full IMMUNITYBIO, INC. analysis at Buy Like Buffett